Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > de G

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Dec 13, 2023 4:07pm

136 Views

Post# 35783036

RE:RE:de G

I could be wrong but from sedi this is not showing that he took 350,000 shares, instead it is showing that he was awarded another 350,000 options unless I am reading this wrong.

Filed 2023-12-13 14:54 Tx date 2023-12-08 $ONC Oncolytics Biotech Inc. Coffey, Matthew 4 - Director of Issuer, 5 - Senior Officer of Issuer Direct Ownership Rights Restricted Share Units 56 - Grant of rights +93,800 vol 174,500 Filed 2023-12-13 14:52 Tx date 2023-12-08 $ONC Oncolytics Biotech Inc. Coffey, Matthew 4 - Director of Issuer, 5 - Senior Officer of Issuer Direct Ownership Options 50 - Grant of options $668,500 +350,000 vol $1.91 each 1,855,631

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"